Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most. Invivyd's investigational monoclonal antibody VYD2311 showed superior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results